The COVID-19 pandemic did not negatively impact frequency or continuity of outpatient care in Alberta, Canada.

The COVID-19 pandemic did not negatively impact frequency or continuity of outpatient care in Alberta, Canada.

Publication date: Sep 21, 2023

Outpatient care patterns have changed markedly during the COVID-19 pandemic. In this population-based retrospective cohort study, we compared the frequency of outpatient care (whether in-person or virtual) and continuity of care for all community-dwelling adults in Alberta between March 1, 2019 and February 29, 2020 (pre-pandemic) versus March 1, 2020 to February 28, 2021 (pandemic). We calculated provider continuity using Breslau’s Usual Provider Continuity (UPC) for patients with at least 2 outpatient encounters. In 2019-20, 594,350 (98. 4%) of 603,877 community-dwelling adults with ambulatory care sensitive conditions (ACSC) had [Formula: see text] 1 outpatient visit (median 8 visits, mean UPC score 0. 61, SD 0. 23), compared to 566,569 (98. 6%) of 574,613 (median 8 visits, mean UPC score 0. 67, SD 0. 23) during the first year of the pandemic. Similar patterns were seen for adults without ACSC: 2,207,710 (93. 9%) of 2,350,147 had [Formula: see text] 1 outpatient visit (median 3 visits, mean UPC score 0. 61, SD 0. 24) pre-pandemic compared to 2,113,239 (93. 5%, median 4 visits, mean UPC 0. 67, SD 0. 24) in the first year of the pandemic. Thus, the COVID-19 pandemic did not impact frequency of follow-up while continuity of care improved both for patients with or without ACSC in Alberta, Canada.

Open Access PDF

Concepts Keywords
Breslau Acsc
Canada Adults
Outpatient Alberta
Pandemic Canada
Care
Compared
Continuity
Covid
Frequency
Median
Outpatient
Pandemic
Score
Upc
Visits

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease VO frequency
disease VO Canada
disease VO population
drug DRUGBANK Coenzyme M
disease MESH asthma
pathway KEGG Asthma
disease MESH chronic obstructive pulmonary disease
disease MESH heart failure
disease MESH coronary disease
disease MESH hypertension
disease MESH epilepsy
drug DRUGBANK Trestolone
disease MESH emergency
disease MESH diabetes mellitus
disease MESH comorbidity
drug DRUGBANK Pirenzepine
disease MESH death
disease MESH chronic conditions
disease MESH atrial fibrillation
disease MESH cancer
drug DRUGBANK Phencyclidine
disease IDO quality
disease VO effectiveness
disease IDO blood
drug DRUGBANK Cholesterol
disease VO ProHIBiT

Original Article

(Visited 1 times, 1 visits today)